Business Context and Reporting Period
Company: Sanofi-Synthelabo (now Sanofi)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Half of 2003 (ended June 30, 2003)
Release Date: July 23, 2003
Accounting Basis: French GAAP
The company reported strong consolidated sales growth driven by key product launches and market expansion, particularly in the United States, despite unfavorable currency fluctuations.
Key Financial Metrics
Revenue and Growth
- Consolidated Sales (H1 2003): 3,903 million euros.
- Comparable Basis Growth: +14.4% (H1 2003 vs. H1 2002).
- Reported Basis Growth: +6.1% (H1 2003 vs. H1 2002).
- Q2 2003 Sales: 1,944 million euros (+15.4% comparable, +6.5% reported).
- Developed Sales (H1 2003): 4,913 million euros (+15.0% comparable).
Regional Performance (H1 2003)
| Region | Sales (M EUR) | Comparable Growth | Reported Growth |
|---|---|---|---|
| Europe | 2,320 | +7.9% | +6.6% |
| United States | 884 | +40.1% | +16.9% |
| Rest of World | 699 | +11.0% | -6.7% |
| Total | 3,903 | +14.4% | +6.1% |
Top Product Performance (H1 2003)
- Eloxatin (Oxaliplatin): 384 million euros (+220.0% comparable). Driven by US success (213 million euros).
- Stilnox/Ambien (Zolpidem): 627 million euros (+20.8% comparable).
- Plavix (Clopidogrel): 612 million euros (+27.0% comparable). Excluding sales to partner BMS, growth was 38.3%.
- Aprovel (Irbesartan): 334 million euros (+29.5% comparable).
Profitability, Cash Flow, and Debt
The filing text does not provide specific values for net profit, operating margins, cash flow, or total debt for the period. The report focuses primarily on sales volume and growth rates.
Material Changes vs. Prior Period
- Currency Impact: Unfavorable impact of 7.8 percentage points on reported growth. Approximately half was due to the strengthening of the Euro against the US Dollar (Euro appreciated >20% vs. H1 2002), with the remainder due to weakness in Latin American and Asian currencies.
- Structural Changes: Unfavorable impact of 0.5 percentage points, primarily due to the change from full consolidation to 51% proportionate consolidation of Sanofi-Synthelabo-Fujisawa (Taiwan) in May 2002.
- US Market Acceleration: US sales grew 40.1% on a comparable basis, significantly outpacing Europe and Rest of World, driven by Eloxatin and Ambien.
- Portfolio Shift: The top 10 products accounted for 65.9% of H1 2003 sales, up from 57.9% in H1 2002. Conversely, the rest of the portfolio declined 7.6% on a comparable basis, largely due to the loss of patent protection for Ticlid and Corotrope/Primacor.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2003 Forecast Confirmed: Management confirmed the full-year 2003 forecasts announced in February 2003.
- Sales Growth: Expected to achieve a similar level of comparable-basis consolidated sales growth as in 2002.
- Earnings Per Share (EPS): Forecast to increase close to 20% (before exceptional items and goodwill amortization), assuming an exchange rate of 1 Euro = 1 USD. Sensitivity is estimated at 1% EPS growth change for every 3-cent movement in the dollar exchange rate.
- H1 EPS: Anticipated to be in line with full-year forecasts.
Risks and Contingencies
- Forward-Looking Statements: Results may differ due to the ability to expand profitably in the US, R&D success, intellectual property protection, and healthcare reimbursement/pricing reforms (specifically in the US and France).
- Inventory Dynamics: US invoiced sales for Plavix were influenced by partner (Bristol-Myers Squibb) inventory workdowns in the prior year, creating a favorable comparative base.
Investor Verification Checklist
- Currency Sensitivity: Verify the impact of the strong Euro on future reported earnings, given the significant US revenue exposure.
- Plavix Partnership: Confirm the sustainability of Plavix growth independent of partner inventory fluctuations and the specific terms of the BMS alliance.
- Patent Expirations: Assess the long-term impact of the decline in the "rest of portfolio" due to generic competition for Ticlid and Corotrope/Primacor.
- Eloxatin Trajectory: Monitor the sustainability of Eloxatin's 220% growth rate as it matures in the market.
- EPS Sensitivity: Validate the 1% EPS sensitivity per 3-cent dollar movement against current FX hedging strategies.